A PHASE 1 STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF TWO CAPSULE FORMULATIONS OF IXAZOMIB, AN ORAL PROTEASOME INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA

Wednesday, July 26, 2017